We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+45.97%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
+$1.91B
Cap. Flow
+$58.2M
Cap. Flow %
0.82%
Top 10 Hldgs %
40.22%
Holding
232
New
17
Increased
84
Reduced
52
Closed
24

Top Buys

Rank Stock Value
1
GBIO
Generation Bio
GBIO
+$32.1M
2
SYK icon
Stryker
SYK
+$27.9M
3
PODD icon
Insulet
PODD
+$24.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
5
DVA icon
DaVita
DVA
+$23.4M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$34.5M
3
ILMN icon
Illumina
ILMN
+$34.1M
4
MRNA icon
Moderna
MRNA
+$33.1M
5
AKCA
Akcea Therapeutics Inc
AKCA
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
2 Industrials 0.58%
3 Technology 0.42%
4 Communication Services 0.29%
5 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNMK
76
DELISTED
GenMark Diagnostics, Inc
GNMK
$21.9M 0.31%
1,489,284
-922,642
-38% -$9.37M
INSP icon
77
Inspire Medical Systems
INSP
$1.53B
$21.3M 0.3%
244,250
+107,025
+78% +$8.23M
CHRS icon
78
Coherus Oncology
CHRS
$219M
$20.7M 0.29%
1,157,400
+1,108,900
+2,286% +$18.8M
AKCA
79
DELISTED
Akcea Therapeutics Inc
AKCA
$20M 0.28%
1,462,296
-1,741,948
-54% -$26.9M
SWAV
80
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$19.8M 0.28%
418,089
+93,428
+29% +$3.85M
LVGO
81
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$19.3M 0.27%
257,258
-13,974
-5% -$731K
GKOS icon
82
Glaukos
GKOS
$9.13B
$19M 0.27%
493,811
+81,188
+20% +$3.02M
AXNX
83
DELISTED
Axonics, Inc. Common Stock
AXNX
$18.1M 0.26%
516,428
+337,095
+188% +$11.6M
PEN icon
84
Penumbra
PEN
$12.5B
$17.6M 0.25%
98,152
+16,013
+19% +$2.78M
GTHX
85
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$17.5M 0.25%
721,925
– –
GMED icon
86
Globus Medical
GMED
$10.3B
$16.6M 0.23%
347,729
+9,662
+3% +$466K
CHNG
87
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$16.3M 0.23%
1,455,240
+377,665
+35% +$4.24M
ONEM
88
DELISTED
1Life Healthcare
ONEM
$16.2M 0.23%
446,807
+196,807
+79% +$5.54M
CVS icon
89
CVS Health
CVS
$137B
$15.1M 0.21%
231,681
+18,700
+9% +$1.18M
NEO icon
90
NeoGenomics
NEO
$1.85B
$15M 0.21%
+485,470
New +$13.5M
RMD icon
91
ResMed
RMD
$28.8B
$14.9M 0.21%
77,805
-700
-0.9% -$115K
VEEV icon
92
Veeva Systems
VEEV
$32.1B
$14.8M 0.21%
63,056
+12,172
+24% +$2.41M
REGN icon
93
Regeneron Pharmaceuticals
REGN
$70.5B
$14.4M 0.2%
23,100
+4,000
+21% +$2.27M
ZLAB icon
94
Zai Lab
ZLAB
$2.32B
$14.4M 0.2%
175,100
+21,100
+14% +$1.43M
OMCL icon
95
Omnicell
OMCL
$2.06B
$14.3M 0.2%
202,131
+5,995
+3% +$410K
NVRO
96
DELISTED
NEVRO CORP.
NVRO
$13.4M 0.19%
111,762
+31,856
+40% +$3.78M
QTRX icon
97
Quanterix
QTRX
$184M
$13.1M 0.19%
477,515
+31,842
+7% +$805K
AMED
98
DELISTED
Amedisys
AMED
$12.1M 0.17%
61,143
– –
TRHC
99
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$11.9M 0.17%
216,581
+7,772
+4% +$445K
TXG icon
100
10x Genomics
TXG
$5.49B
$11M 0.16%
123,077
+29,230
+31% +$2.28M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2020 Portfolio in Review

As of Q2 2020, Bellevue Group held 232 positions worth $7.07B, up 37% from $5.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group's Q2 2020 filing shows 17 new, 84 increased, 52 reduced and 24 closed positions. Its largest new stake was Generation Bio: 144,000 shares worth $30.2M. The largest sale was Vertex Pharmaceuticals, an estimated $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2020 buy was Generation Bio: 144,000 shares worth $30.2M.
  • Bellevue Group added most to Stryker in Q2 2020, an estimated $27.9M increase.
  • Bellevue Group's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $78.8M.
  • Bellevue Group fully exited QuidelOrtho in Q2 2020, selling an estimated $11.1M.
  • Bellevue Group's ten largest holdings make up 40% of its $7.07B portfolio in Q2 2020.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2020.
  • Bellevue Group's portfolio value rose 37% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.